THX PharmaSTU:3VG +7.97%31 3-Year ROIIC % is 74.55 as of Dec. 2025. GuruFocus rates STU:3VG with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,321 Biotechnology companies, THX Pharma ranks better than 75.7% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
THX Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 74.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for THX Pharma's 3-Year ROIIC % or its related term are showing as below:
STU:3VG's 3-Year ROIIC % is ranked better than 75.7% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs STU:3VG: 74.55
THX Pharma (STU:3VG) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
THX Pharma 3-Year ROIIC % Related Terms
THX Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for THX Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3VG vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, THX Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where THX Pharma's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
THX Pharma (STU:3VG) has a 3-Year ROIIC % of 74.55 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #321 out of 1321 companies in the Biotechnology industry, placing it in the top 24.3%.
Is THX Pharma's 3-Year ROIIC % too high?
THX Pharma's current 3-Year ROIIC % is 74.55. Based on the distribution chart, THX Pharma ranks #321 out of 1321 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, THX Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #321 out of 1321 companies for 3-Year ROIIC %. This places THX Pharma in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on THX Pharma and its competitors. THX Pharma's current 3-Year ROIIC % is 74.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current 3-Year ROIIC % of 74.55. The current 3-Year ROIIC % is 74.55. THX Pharma's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current 3-Year ROIIC % is 74.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
31GF Score
Get the complete analysis for STU:3VG
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3VG has been successfully added to your 
